Potential clinical applications of halichondrins in breast cancer and other neoplasms

Vanesa Ortega1, Javier Cort&eacute;s1,21Department of Oncology, Vall d&rsquo;Hebr&oacute;n University Hospital, Barcelona, Spain; 2Vall d&rsquo;Hebron Institute of Oncology (VHIO), Barcelona, SpainAbstract: Halichondrin B is a large polyether macrolide found in a rare...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ortega V, Cortes J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4c1c4f3606b64965b8607abde028cfec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c1c4f3606b64965b8607abde028cfec
record_format	dspace
spelling	oai:doaj.org-article:4c1c4f3606b64965b8607abde028cfec2021-12-02T07:46:18ZPotential clinical applications of halichondrins in breast cancer and other neoplasms1179-1314https://doaj.org/article/4c1c4f3606b64965b8607abde028cfec2012-02-01T00:00:00Zhttp://www.dovepress.com/potential-clinical-applications-of-halichondrins-in-breast-cancer-and--a9219https://doaj.org/toc/1179-1314Vanesa Ortega1, Javier Cort&eacute;s1,21Department of Oncology, Vall d&rsquo;Hebr&oacute;n University Hospital, Barcelona, Spain; 2Vall d&rsquo;Hebron Institute of Oncology (VHIO), Barcelona, SpainAbstract: Halichondrin B is a large polyether macrolide found in a rare Japanese sponge, Halichondria okadai and has been shown to have anticancer activity. Eribulin mesylate is a completely synthetic analog of halichondrin B with a unique mechanism of action relative to other antimicrotubule agents. This new agent has demonstrated activity in preclinical studies, and it is being developed for the treatment of different tumor types. Eribulin has been approved by the United States Food and Drug Administration and the European Medicines Agency as late-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. It has demonstrated superiority over other treatments in overall survival (OS) (hazard ratio: 0.81, P = 0.041), leading to its regulatory approbation for clinical practice use. Median OS for the eribulin-treated group was 13.1 months versus 10.6 months in the physician&rsquo;s treatment-of-choice group. Eribulin demonstrated a manageable toxicity profile. Most common adverse events associated with treatment were mild neutropenia and fatigue, mainly of grade 1 or 2. In contrast to other antimicrotubule agents, eribulin has a relatively low incidence of peripheral neuropathy and alopecia. Eribulin has been extensively studied in breast cancer and is currently being developed for treatment of other cancer types. Eribulin has demonstrated activity in Phase II trials in non-small cell lung cancer, pancreatic cancer, urothelial tract cancer, and sarcomas. Further studies in these cancers are ongoing. This article reviews pharmacology, mechanism of action, pharmacokinetics and efficacy of eribulin in breast cancer and other neoplasms.Keywords: halichondrin B, eribulin, antimicrotubule, metastatic breast cancerOrtega VCortes JDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 9-19 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ortega V Cortes J Potential clinical applications of halichondrins in breast cancer and other neoplasms
description	Vanesa Ortega1, Javier Cort&eacute;s1,21Department of Oncology, Vall d&rsquo;Hebr&oacute;n University Hospital, Barcelona, Spain; 2Vall d&rsquo;Hebron Institute of Oncology (VHIO), Barcelona, SpainAbstract: Halichondrin B is a large polyether macrolide found in a rare Japanese sponge, Halichondria okadai and has been shown to have anticancer activity. Eribulin mesylate is a completely synthetic analog of halichondrin B with a unique mechanism of action relative to other antimicrotubule agents. This new agent has demonstrated activity in preclinical studies, and it is being developed for the treatment of different tumor types. Eribulin has been approved by the United States Food and Drug Administration and the European Medicines Agency as late-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. It has demonstrated superiority over other treatments in overall survival (OS) (hazard ratio: 0.81, P = 0.041), leading to its regulatory approbation for clinical practice use. Median OS for the eribulin-treated group was 13.1 months versus 10.6 months in the physician&rsquo;s treatment-of-choice group. Eribulin demonstrated a manageable toxicity profile. Most common adverse events associated with treatment were mild neutropenia and fatigue, mainly of grade 1 or 2. In contrast to other antimicrotubule agents, eribulin has a relatively low incidence of peripheral neuropathy and alopecia. Eribulin has been extensively studied in breast cancer and is currently being developed for treatment of other cancer types. Eribulin has demonstrated activity in Phase II trials in non-small cell lung cancer, pancreatic cancer, urothelial tract cancer, and sarcomas. Further studies in these cancers are ongoing. This article reviews pharmacology, mechanism of action, pharmacokinetics and efficacy of eribulin in breast cancer and other neoplasms.Keywords: halichondrin B, eribulin, antimicrotubule, metastatic breast cancer
format	article
author	Ortega V Cortes J
author_facet	Ortega V Cortes J
author_sort	Ortega V
title	Potential clinical applications of halichondrins in breast cancer and other neoplasms
title_short	Potential clinical applications of halichondrins in breast cancer and other neoplasms
title_full	Potential clinical applications of halichondrins in breast cancer and other neoplasms
title_fullStr	Potential clinical applications of halichondrins in breast cancer and other neoplasms
title_full_unstemmed	Potential clinical applications of halichondrins in breast cancer and other neoplasms
title_sort	potential clinical applications of halichondrins in breast cancer and other neoplasms
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/4c1c4f3606b64965b8607abde028cfec
work_keys_str_mv	AT ortegav potentialclinicalapplicationsofhalichondrinsinbreastcancerandotherneoplasms AT cortesj potentialclinicalapplicationsofhalichondrinsinbreastcancerandotherneoplasms
_version_	1718399152176496640

Potential clinical applications of halichondrins in breast cancer and other neoplasms

Ejemplares similares